Oruka Therapeutics, Inc. Income Statement
ORKA / Health Care|15 years of annual SEC 10-K data (FY2010-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | - | - | - |
| SG&A Expense | $13.1M | $6.3M | $5.5M | $4.8M | $4.0M | $3.9M | $4.6M | $4.3M | $4.4M | $4.1M | $4.0M | $4.0M | $3.2M | $5.0M | $6.1M |
| R&D Expense | $75.1M | $1.0M | $13.8M | $5.0M | $1.8M | $4.2M | $14.1M | $12.3M | $7.1M | $5.6M | $2.9M | $2.9M | $1.1M | $2.3M | $3.1M |
| Operating Income | -$88.1M | -$7.3M | -$19.3M | -$9.8M | -$5.8M | -$8.1M | -$18.7M | -$16.6M | -$11.5M | -$9.7M | -$6.9M | -$6.9M | -$4.3M | -$7.4M | -$9.2M |
| Interest Expense | - | - | - | $9.0K | $7.0K | $8.0K | $6.0K | $6.0K | $4.0K | $3.0K | $4.0K | $4.0K | $3.0K | $5.0K | $8.0K |
| Income Tax | - | $0 | $0 | -$9.0K | -$167.0K | -$31.0K | -$61.0K | $0 | $0 | $0 | $0 | $0 | -$2.3M | -$2.3M | - |
| Net Income | -$83.7M | -$5.3M | -$19.3M | -$9.7M | -$5.5M | -$7.9M | -$18.5M | -$16.4M | -$11.4M | -$9.7M | -$6.9M | -$6.9M | -$4.3M | -$5.4M | -$8.4M |
| EPS (Basic) | -$3.87 | -$0.69 | -$1.39 | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS (Diluted) | -$3.87 | -$0.69 | -$1.39 | -$2.07 | -$4.15 | -$10.31 | -$1.77 | -$1.81 | -$1.82 | -$3.31 | -$1.04 | - | - | - | - |
| Shares Outstanding | 16.8M | 14.4M | 14.4M | 9.5M | 1.6M | 773.6K | 11.8M | 9.1M | 9.1M | 3.0M | 15.7M | 8.6M | 2.2M | 1.7M | - |